Target Validation Information
TTD ID	T73676
Target Name	Synaptic vesicle glycoprotein 2A (SV2A)
Type of Target	Successful
Drug Potency against Target	Brivaracetam	Drug Info	IC50 = 80 nM	[1]
Action against Disease Model	Brivaracetam	Drug Info	UCB-34714 binds the LBS with pIC50 = 7.1. UCB-34714 induces the most potent and complete seizure suppression in animal models at doses devoid of side effects. Further testing ofUCB-34714 in animal models mimicking several other CNS diseases, such as neuropathic pain and essential tremor, also confirmed promising pharmacological activities	[2]
References
REF 1	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
REF 2	Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem. 2004 Jan 29;47(3):530-49.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.